Introduction ance of the available data strongly argues in favor of the clinical use of cytokines. This view is emphasized in the recent The development of in vitro marrow clonogenic culture sysreview by Geller, 2 and the overall data will be summarized tems has led to the discovery of a family of interacting hemain these pages. topoietic growth factors which have recently been demonThe data that are herein considered relate mostly to acute strated to have critical physiologic roles for controlling myelogenous leukemia (AML) where historical controversy hematopoiesis in vivo. Of the many hematopoietic growth abounds, owing to the effect of cytokines on the leukemia factors which have been cloned, only granulocyte colonyprogenitor cells. The data for acute lymphocytic leukemia stimulating factor (G-CSF) and granulocyte-macrophage col-(ALL) are more appropriately considered with the lymphoproony-stimulating factor (GM-CSF) have seen widespread cliniliferative disorders. In fact, several clinical trials have been cal use. Some trials have begun with interleukin-3 (IL-3), reported in ALL, mostly encouraging their use, especially in macrophage CSF (M-CSF), (stem cell factor) SCF, IL-6, IL-1 and older adults. [5] [6] [7] Nonetheless, several aspects described in this thrombopoietin. GM-CSF and IL-3 have predominantly prochapter for AML are probably equally applicable to ALL, liferative effects on early hematopoietic cell compartments, especially the emerging data on direct antimicrobial action whereas G-CSF and M-CSF, or CSF-1, have major differenof cytokines. tiation as well as proliferative effects on lineage-specific cells.
There are many potential applications of colony-stimulating factors in the treatment of acute leukemia (Table 1) . These Effects of growth factors on leukemic cell proliferation include reducing the period of neutropenia, inducing leukemic cells into the S-phase of the cell cycle, enhancing antiSome AML blasts possess receptors for the clinically available microbial function, protecting stem cells, inducing differengrowth factors, G-CSF and GM-CSF. 8 G-CSF is produced by tiation of leukemic cells, interrupting autocrine-paracrine fibroblasts, monocytes, and endothelial cells. AML blasts may loops, and directly inhibiting leukemic cell proliferation.
possess G-CSF receptors and may demonstrate enhanced proSeveral excellent reviews have recently been published in liferation in the presence of G-CSF in vitro. Autocrine prothis area. [1] [2] [3] [4] In spite of extensive data, some with unequivoduction of G-CSF by AML cells has also been demonstrated. cally positive results, some of these reviews 1, 3, 4 lean heavily G-CSF has been found to have a protective effect on leukemic on the cautionary approach. Bü chner et al 4 summarize their cell programmed death. 9 The role of G-CSF in the biology of AML is probably a complex one. There is evidence that G-CSF induces tyrosine phosphorylation of p95vav in primary Table 1 Potential uses of cytokines in AML human acute myelogenous leukemic cells but not in neutrophils. 10 Precise signalling pathways for G-CSF in primary AML 1 Reducing period of neutropenia blasts have not yet been completely described.
2 Enhancement of antimicrobial function 3 Recruitment of cells into S-phase of the cell cycle (priming) cells. 19 Khoury et al 20 have reported that when CD34 + /c-kit receptor.
IL-4
The expression of IL-6, IL-6 receptor, and gp130, has been expressed IL-6. IL-6R was expressed in all cases of leukemia tested, and gp130 was likewise ubiquitously expressed. Point mutations of n-ras have been associated with expression of kin-11 (IL-11) is a pleiotropic cytokine. By itself, IL-11 has been found to be ineffective in supporting myeloid leukemic IL-6 in AML cells.
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Based upon the findings that AML blasts have receptors for cell growth, but it can enhance growth stimulated by IL-3, GM-CSF, or c-kit ligand. Thymidine suicide studies in AML multiple growth factors and can in certain instances proliferate in response to exogenous administration of growth factors in patient samples showed that 40 to 50% of the blast cells were in S-phase when exposed for 16 h to IL-3. This increased to vitro, the simultaneous exposure of AML cells in vivo to multiple growth factors would be expected to result in either addi-70 to 90% in response to either IL-11 or IL-6. Both kit ligand and IL-11 have also been found to support the clonogenic tive, inhibitory, or synergistic effects. That these effects of growth factors on AML blasts are complex and interactive is growth of AML blasts. 12 Broudy et al 13 have found receptors for stem cell factor supported by work such as that reported by Wagteveld et al. 23 They found that IL-4 enhanced proliferation in a subset of (SCF) (c-kit ligand) on blasts from 20/20 AML patients. Both high-and low-affinity binding sites were identified, but the AML cells, and the combination of IL-1 and IL-4 was additive in about 50% of cases studied. It was found that IL-1 induced number of receptors per cell did not correlate with growth response to SCF. SCF was found to act synergistically with ILthe endogenous secretion of GM-CSF, IL-6, and TNF in most cases, but no secretion of growth factors was induced by IL-3 or GM-CSF to stimulate colony growth from the marrow cells of a portion of patients with AML. Both the c-kit and 4 alone. In some cases, however, IL-4 suppressed the IL-1-induced secretion of GM-CSF, TNF, and IL-6. In addition to GM-CSF receptor have been found to activate the Na+/H+ antiporter and to suppress apoptosis in leukemia cells. 14 the complex interactions of growth factors in vivo, there is significant heterogeneity in AML blasts as regards the Kubota et al 15 reported that 24 out of 35 (69%) of myeloid leukemia patients examined had significant c-kit-positive blast expression of growth factor receptors or their ability to respond to growth factors in vitro and presumably in vivo. The ability of some AML blasts to proliferate in response to growth factors led to concerns that use of pharmacological CD34 was significant. Fifteen cases of myeloid leukemia were positive for lymphoid markers, and those with lymphoid markdoses of growth factors might stimulate leukemic growth in various clinical situations. Despite the presence of G-CSF and ers had the highest expression of c-kit. SCF enhanced the colony growth in five out of six AML cases tested which GM-CSF receptors on AML blasts, growth factor administration during induction or consolidation treatment courses for expressed the c-kit molecule.
mRNA transcripts of thrombopoietin (TPO) were detected AML does not seem to stimulate the growth of leukemia.
25-28
There is no evidence of stimulation of the growth of myeloid in 18 of 50 AML cases and in some myeloid leukemia cell lines by RT-PCR in one study. 16 TPO was coexpressed with leukemia cells by G-CSF if it is used for a short period of time and if the number of leukemic cells is reduced by chemoc-mpl, the ligand for thrombopoietin, in 10 of 50 AML cases. As expected, TPO and c-mpl were observed with high fretherapy. Also, there is no evidence that GM-CSF or G-CSF administration increases relapse rates of leukemia after quency in AML cases of megakaryoblastic (FAB-M7) type. TPO was not found in the conditioned medium in TPO chemotherapy once remission is attained.
26,29-31
Growth factors currently available for clinical use can thus mRNA-positive leukemia cells cultivated in vitro. Matsumura et al 17 found that recombinant human thrombopoietin was generally be administered safely to patients with AML. Major side-effects which may be encountered are fever, rashes, able to support proliferation of AML cells for 2 to 4 weeks in four of 15 cases which were M0, M2, M4, and M7 by FAB capillary leak syndromes, and joint aches. These toxicities are also common when growth factors are not used. 2 When subtype. In two cases, some stimulation of megakaryocytic differentiation was noted. What implications this might have growth factors are used in leukemia, no increase in early relapse has been demonstrated. 26, 32 This is discussed in further for clinical use of c-mpl ligand in AML remains uncertain as regards ability of this growth factor to increase proliferation of detail below in the context of clinical usage of G-CSF and GM-CSF to reduce neutropenia. AML blasts. Fresh myeloid leukemia blast cells and myeloid leukemic cell lines also express the FLT3 receptor.
18 FLT3 ligand is a hematopoietic growth factor that plays a key role Reducing period of neutropenia in growth of primitive hematopoietic cells.
AML blasts also express both tumor necrosis factor (TNF) Early death during induction therapy for acute myelogenous leukemia (AML) still remains an important clinical problem. receptors; TNF-Rp55 and the TNF-Rp75. TNF-alpha stimulation of AML blasts occurs through both p55 and p75 TNF The mortality rate increases with age and, for patients over 55 to 60 years, the treatment-related early death rate is on the receptors as assessed by receptor-specific antibody blocking. TNF-alpha-signalled growth inhibition is mediated via only order of 20 to 40%.
33-37
330 Table 3 also indicates that stimulation of leukemia -a major early concerntered this at varying points ranging from start of induction therapy to immediately following the completion of such therapy. appears not to be a relevant clinical problem. Only one recent trial, using the E. coli form of GM-CSF, 44 reported this to be In these latter studies, it may indeed be difficult to ascertain the effect of cytokines that one is testing; whether a stimua significant clinical problem, albeit in a small cohort of patients.
latory effect on leukemic blasts -a potential positive or negative effect due to 'priming' -vs stimulation of normal hematoIt is perhaps surprising that in spite of a multitude of clinical studies revolving around the use of hematopoietic growth facpoiesis. This could make interpretation of the data difficult because of these separate yet possibly interactive effects. tors during induction therapy for acute leukemia, much controversy abounds. A closer look, however, reveals a great
Other considerations revolve around the use of different study products, perhaps also hindering direct comparisons as variability in study conditions (Table 4 ) and there are very few identical study designs. In fact, most studies may have fundathere may be subtle differences even among different cellular preparations of the same cytokine. The statistical endpoints mental differences in their design that impact on the results 
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used in the design of many of these studies need to be very clinical trials has never been proven. It is also possible 54 that the functional activation of leukocytes, including the carefully considered. Some of the studies were designed and sized to show differences in hematopoietic recovery, for increased generation of leukotrienes, may also explain some of the adverse effects caused by GM-CSF -which, in turn, example, but not to show differences in complete response rates or survival. Because of the magnitude of the potential would explain the greater clinical toxicity seen with the nonglycosylated forms of GM-CSF. difference in days to hematopoietic recovery, the number of patients required to demonstrate such a difference are far It is not the intent of this article to describe all published trials in great detail. A study by the Eastern Cooperative fewer than differences in response rate or survival which, in a typical AML study, require 300 to 400 patients. It cannot be Oncology Group 26 will be described as a prototype with which other studies can be compared. The reason for this overemphasized that in such studies, a lack of a statistically significant response rate does not demonstrate a lack of choice is the fact that this was the first reported prospective placebo-controlled study 55 and is a study that has shown the response, but rather the inability to make any substantive conclusions due to the intrinsic study design.
most clear-cut benefit for cytokines following induction therapy in AML. In this study, adult patients over the age of 55 Virtually all reports in the literature make generic references to G-CSF and GM-CSF. However, this may not be appropriate, were treated with daunorubicin 60 mg/m 2 intravenously for 3 days and cytosine arabinoside 100 mg/m 2 intravenously for particularly in the case of GM-CSF. Because of differences in physico-chemical properties and pharmacokinetics, the Food 7 days. A bone marrow was performed 3 days after completion of and Drug Administration (FDA) in the US decided to assign different generic names for GM-CSF, based on the expression one or two cycles of chemotherapy (day 10), and if this was aplastic, yeast-derived GM-CSF at a dose of 250 g/m 2 or an system used. Sargramostim is a glycosylated GM-CSF product in yeast and molgramostim is the non-glycosylated GM-CSF equal volume of placebo, was administered starting on day 11 until neutrophil recovery to 1500/l. Those patients who product in E. coli. The glycosylated product has a slower rate of distribution than the non-glycosylated GM-CSF and has a went into complete remission received consolidation therapy with cytosine arabinoside 1.5 g/m 2 intravenously every 12 h high rate of leukotriene metabolism. The increased leukotriene production is thought to be related to the increased clinifor a total of 12 doses. Patients received the same randomized study drug in consolidation as they received during induction cal toxicity that is seen with a non-glycosylated GM-CSF; most importantly, the increased fluid retention, respiratory toxicity, in order to avoid any potential cross-over effects.
One hundred and twenty-four patients were entered in the fevers and myalgias. The differences in toxicity and physicochemical as well as pharmacokinetics have been clearly study and the overall complete remission rate was 60% among patients receiving GM-CSF and 44% among those on established (Table 5) . 53 It is not known, however, whether there are any clear differences in the clinical spectrum of placebo (P = 0.07). For those patients aged 56 to 65 years, the differences are 68 vs 48% and for those over 65, the difference activity between the two products, but such differences could explain some of the conflicting results from clinical trials. One was 45 vs 31% for GM-CSF and placebo, respectively. Once again, it is important to remember that this study was not sized report 54 described the differences in GM-CSF serum concentrations in healthy human volunteers treated with the nonto show differences in complete remission rate. The mortality following study drug administration (after day 11) was 6% glycosylated E. coli GM-CSF and the glycosylated Chinese hamster ovary GM-CSF. A peak effect with a more rapid among patients receiving GM-CSF and 15% among patients receiving placebo (P = 0.18), but if this is extended to within increase and decrease in GM-CSF serum concentrations was evident in the non-glycosylated GM-CSF product. What was 30 days of study drug completion, a very significant difference (P = 0.015) was seen for GM-CSF (7.7%) vs placebo (28%). more important was that the slower rate of distribution in the glycosylated GM-CSF product corresponded to a more susImportantly, there were very significant differences in the death rate from pneumonia and from fungal infections. The tained increase in the actual leukocyte counts in these volunteer donors. This clearly provides a potentially important neutrophil recovery was significantly shortented among patients receiving GM-CSF although there was no difference theoretical difference that could lead to marked clinical effects, although the significance of this finding in current in the platelet or red cell recovery (Table 6 ).
Based on an intent-to-treat analysis, the overall survival was improved in patients who received GM-CSF compared with Table 5 Recombinant granulocyte-macrophage colony-stimulatplacebo (323 vs 145 days; P = 0.048). This difference ing factor (GM-CSF) appeared to be almost entirely due to death within the first 2 months.
Properties Yeast E. coli (molgramostim)
A major concern in these studies has been the fact that even if cytokines reduce the morbidity and mortality, this use may general, the overwhelming data in several thousand patients lead to an increased rate of relapse. However, in this study, has allayed any fears regarding the safety of cytokines during among all patients who entered complete remission, the induction. Table 7 also emphasizes the great variability relapse rate in the GM-CSF and placebo patients are viramong the studies; in the start day of administration; whether tually identical. marrow aplasia had been achieved; and in the type of cytoClearly, other studies do not show similar results. The large kine used. It is also apparent from this Table that virtually all  study by the Cancer and Leukemia Group B 25 demonstrated studies using yeast-derived GM-CSF and G-CSF show a siga small, but significant, difference in neutrophil recovery (15 nificantly enhanced neutrophil recovery period. The data with vs 17 days) in favor of GM-CSF. However, the authors E. coli-derived GM-CSF are less impressive with two studdescribe this to be of no clinical significance, and there were ies 45, 46 showing a clear difference, another study showing a no differences in the infection rate, morbidity or mortality in minor, but significant difference 25 and a further study showing the study. It is important to note that the E. coli form of GMno difference. 44 Table 7 further indicates that most studies CSF was used; patients received GM-CSF without any attempt using yeast-derived GM-CSF or G-CSF show at least a trend to ascertain whether marrow aplasia had been reached and towards an improved complete remission rate, and one study there was a significant dropout rate -approximately 30% -shows a very significant difference. 49 Two studies with G-CSF in patients taking study drug in both arms. The fact that this show no such difference. 51, 52 No such apparent effect is occurred in both arms suggests a great degree of perceived shown in any of the studies using the E. coli form of GM-CSF. toxicity using this particular preparation and perhaps, a major At least four of the studies 6,26,30,52 using yeast-derived GMapprehension on the part of investigators using this study drug.
CSF or G-CSF have shown a significant improvement in morOther studies show puzzling and conflicting results. One large bidity and one study 26 shows a significant reduction in morstudy from Europe 49 confirmed the enhanced neutrophil tality using yeast-derived GM-CSF. None of the studies using recovery with G-CSF and showed a statistically significant E. coli-derived GM-CSF describe such an effect. improved complete remission rate but no difference in the Considering that the major reason for the delay in initiating overall survival.
clinical trials in AML has been a concern for safety, it can be While other well-designed studies have not shown an unequivocally stated that this concern has been put to rest. improvement other than neutrophil recovery time, 25, 46, 51 too With the potential benefit demonstrated in so many studies little is made of the benefit from this enhanced neutrophil and the almost universal finding of an improved neutrophil recovery time. In this context, it is probably also important to recovery time, it is not completely clear why there remains note that the largest trial conducted to date 52 showed, in such a great hesitation to use cytokines in acute leukemia. In addition to an enhanced neutrophil recovery time, a signifigeneral, the probability of infection and the risk of increased cant improvement in morbidity with G-CSF. Table 7 summarmorbidity and mortality correlate directly with the severity izes the data from most of the controlled trials of growth facand duration of neutropenia, 56 although such differences may, tors following induction therapy for AML. Although the at times, not be easy to demonstrate objectively. It is, therecomplete data are not always available, Table 7 includes as fore, difficult not to acknowledge a benefit for a patient much data as could be obtained from the published inforundergoing induction therapy for AML who has an improved mation. There are three separate groups identified: the two neutrophil recovery time of approximately 1 week. The sense trials using yeast-derived GM-CSF; the six published trials of of well-being among patients (and physicians) at the earliest G-CSF and four published trials using E. coli-derived GM-CSF.
sign of neutrophil recovery simply cannot be ignored, and Certain points are clear at a glance. Virtually all studies conbased on all of the above, the data would suggest that cytofirm the safety of cytokines in induction. Only one study 44 kines (certainly yeast-derived GM-CSF or G-CSF) should be showed E. coli GM-CSF to have a deleterious effect, but this was not confirmed in any of the other large studies and in administered to all patients undergoing induction therapy for 
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AML who are at high risk for therapy-related morbidity and cytokines with potential anti-fungal activity, although probably less important, are IL-1, IL-2, IL-3, IL-4, IL-6 and G-CSF. mortality.
GM-CSF is likely to play a central role in potential cytokine activity against fungal infections. There are data that suggest that the activity of M-CSF is predominantly mediated through Enhancement of anti-microbial function the release of cytokines such as G-CSF, IL-6 and, most importantly, through activity on monocytes that directly Considerable in vitro work has, over the past decade, established a potential role of cytokines in the direct enhancement release GM-CSF which, in turn, acts on the effector monocytes and neutrophils as well as secreting TNF-␣.
69,70
of anti-microbial function. This of course has important implications in the treatment of patients with AML who experience At the same time, it is important to recognize that macrophages may in fact be a double-edged sword in the immune long periods of treatment-induced neutropenia and its associated infectious complications.
system. While they clearly are a major effector arm of the cellular immune system and are recognized to be critical in Host defense mechanisms involving neutrophils and monocytes are thought to be important in combating fungal infecanti-fungal immunity, they are also the principal target cell for replication of many viral, bacterial, fungal and other pathotions. In vitro, GM-CSF increases the phagocytic and fungicidal activity of neutrophils against Candida albicans and gens and, in fact, mediate much of the damage in inflammatory diseases. There are data that suggest that macrophages Torulopsis glabrata. [57] [58] [59] Similarly, in vitro exposure of peripheral blood mononuclear cells to GM-CSF increases play a major role in the pathology of fungal disease. 71 It is therefore difficult to predict from in vitro data, whether adminphagocytosis of Cryptococcus neoformans, 60 and exposure of monocytes to GM-CSF in vitro results in increased killing istration of GM-CSF or M-CSF, acting directly on macrophages, will in fact benefit or exacerbate a given disease. It is of Candida albicans and Aspergillus fumigatus.
61-64 The mechanism of increased activity against Candida and Asperlikely that clinical results may depend on a delicate balance of the above activities related to specific pathogens, timing of gillus appears to be unrelated to increased phagocytosis; rather it appears to be due to increased oxidative metabolism administration, and dosage. Unfortunately, in spite of fairly abundant data, there has and production of toxic superoxide anions by monocytes. reported on eight patients with AML, ALL and bone marrow with increasing frequency due, at least in part, to the use of broad spectrum antibiotics and the increasing use of indwelltransplant who had Candida, Aspergillus, and Trichosporon. GM-CSF was administered as well as amphotericin B and ing catheters. Despite the development of new anti-fungal agents, amphotericin B remains the mainstay of therapy and, while these authors reported a direct increase in the neutrophil counts, the conclusions were necessarily limited. in general, recovery is associated with resolution of immunosuppression. While the high rate of mortality from dissemiOne of the earliest and most promising phase I studies was conducted in 1991 73 and these authors reported on 24 nated fungal infections has been clearly established, precise data are difficult to obtain and careful consideration must be patients, mostly with Candida, but also some with Aspergillus.
Patients received M-CSF together with amphotericin B. The given to fundamental differences in published reports. Among other things, mortality varies with the time to neutrophilic or neutrophil count, but not the monocyte count, appeared to increase and there was an apparent improvement in six out monocytic recovery as well as whether or not there has been documented organ involvement. It appears that in docuof the 12 evaluable patients. The CGD study group 74 conducted a phase III study and mented fungal infections during neutropenia, the reported mortality ranges from 40 to 100% in acute leukemia and is reported on 130 patients who were treated with interferongamma or placebo. A significantly lower infection rate was still higher in the allogeneic bone marrow transplant recipient. 67 Thus the scope of the problem cannot be overobserved among patients receiving interferon-gamma vs those receiving placebo. There was a marked reduction in the rate emphasized. Prevention of fungal infections during the course of therapy for acute leukemia remains critically important.
of skin and soft tissue infection, but it was also noted that Aspergillus pneumonia occurred in four patients receiving Table 8 summarizes the cytokines for which significant in vitro data suggest important anti-fungal action on the effector placebo and one receiving interferon-gamma. In the previously reported ECOG prospective study of GMcells, specifically neutrophils and monocytes. Besides GM-CSF and M-CSF, there have been some interesting data pub-CSF during induction therapy for AML, 26 improved morbidity and mortality was noted with GM-CSF use. Specifically, the lished with the use of interferon-gamma in this regard. 68 Other mortality from fungal infections among all patients receiving GM-CSF was 1.9% compared with 19% among those receiv- Table 8 Cytokines with potential direct anti-microbial activity ing placebo (P Ͻ 0.001). The primary fungal infections were due to Aspergillus and Candida, as expected. Table 9 emphas-
Cytokines Effector cells
izes the overall mortality among those patients who actually had a documented fungal infection. For patients receiving
GM-CSF Neutrophils
GM-CSF, the overall mortality from fungal infections was
M-CSF Monocytes
13%, and among those receiving placebo, the overall mor-IFN-␥ tality was 75%. 75 Basically, most patients who received GM-CSF survived the fungal infection, and most patients with pla- group is mostly in accordance with the common clinical Table 9 Mortality from fungal infections (phase III ECOG study)
The role that in vivo priming might have on leukemic blasts and ultimate chemotherapy remains uncertain. Some of the
GM-CSF Placebo
earlier studies 79 have suggested that priming with GM-CSF can
increase disease-free survival rates, but an update of these data is less encouraging in this regard. 80 One other study sug- It is important to emphasize at the onset that in vitro data
must be cautiously interpreted when they are described with- following administration of a cytokine needs to be carefully compared with control patients as patients with AML at presentation who are left with no therapy will often change both their cell cycle kinetics as well as increase their blast cell count. [82] [83] [84] experience among older adults where the majority of patients with a documented fungal infection during the neutropenic One of the earliest clinical reports on the use of cytokines to prime leukemic cells was a description in 1991 85 of the phase of induction therapy will not survive this. In evaluating the data from this ECOG study, it is important to emphasize effects of GM-CSF on leukemic cell cycle progression and cell kill with cytosine arabinoside. Following administration of that there were no differences in the treatment among the two groups, including anti-fungal prophylaxis. At the same time, GM-CSF, a three-fold increase in the fraction of blasts in the S-phase was noted. it is important to note that this ECOG study described 20 patients with documented fungal infections and this must be Probably a milestone in the clinical development of the concept of priming was the pioneering work of Bettelheim et considered a relatively small number to, as yet, make definitive conclusions. One of the interesting observations from this al 86 where 18 patients with AML were treated with GM-CSF in combination with cytosine arabinoside and an anthrastudy has been the shortened period of neutropenia associated with the reduction in fungal infections. It is clearly not known cycline. The GM-CSF, in most patients, was started 24 to 48 h prior to chemotherapy and in vitro studies showed recruitment whether direct anti-fungal activity of GM-CSF contributed to this or the reduced mortality was simply a reflection of into the S-phase in all patients. Most importantly, the aplasia was not prolonged and two-thirds of patients went into enhanced neutrophil recovery.
Prospective randomized studies are clearly needed to complete remission after one cycle with no evidence of stimulation of leukemic clonogenic blast cells. This early determine the precise prophylactic, as well as therapeutic, anti-fungal role of these cytokines in patients at high risk for study surprised many and appeared to confound some of the concerns and predictions in that there appeared to be no invasive fungal infections. Because it may be difficult to differentiate a direct antimicrobial role from enhancement of deleterious effect of GM-CSF when administered prior to induction therapy and when it was clearly shown to stimulate neutrophilic and monocytic recovery, a patient population that is severely immunocompromised, but not neutropenic or the leukemia cells. Multiple in vitro studies have reported on GM-CSF being monocytopenic, must form the basis of such prospective studies. One such group may be the post-neutropenic patients given to AML patients either concurrently or just prior to induction therapy. Most of these studies have demonstrated with AML or ALL who have opportunistic infections such as hepatosplenic candidiasis or recipients of allogeneic bone an increase in the percentage of cells in the S-phase. 83, [87] [88] [89] Furthermore, other reports 90 demonstrated an enhancement of marrow transplantation who remain severely immunocompromised, but are not neutropenic or monocytopenic. Clearly, cytosine arabinoside cytotoxicity by both GM-CSF and G-CSF. These authors demonstrated enhanced promotion of cytosine this is an area of great potential for direct cytokine activity and it is hoped that over the next decade, much progress will arabinoside incorporation into DNA as a result of an increased cell fraction in the S-phase. In this study, the AML-19 human be made. leukemia cell line was used as this cell line requires GM-CSF or G-CSF for optimal growth. On the other hand, studies on apoptosis 91 demonstrated Recruitment of cells into the S-phase of the cell cycle that transforming growth factor beta-1 (TGF-␤1) induces cell death in myeloid leukemia by apoptosis. Importantly, the Several investigators have examined the issue of whether hematopoietic growth factors can be utilized to prime leuapoptosis-induced in leukemia cells by TGF-␤1 was inhibited by G-CSF, GM-CSF or IL-3. Of major concern was the demonkemic blasts by increasing the proportion in the active phase of the cell cycle, thereby, theoretically, increasing their susstration that similar inhibition of the apoptosis that is induced by common cytotoxic agents such as vincristine, doxorubicin ceptibility to S-phase active agents such as cytosine arabinoside. In vitro studies have shown that growth factors such as and cytosine arabinoside could be observed using G-CSF or GM-CSF. Basically, this worrisome observation suggested that GM-CSF, stem cell factor (c-kit ligand), IL-3 and others can increase the fraction of leukemic blasts in S-phase. 76 Also, it G-CSF and GM-CSF prevented one of the important mechanisms of control of leukemia and these authors cautioned has been found that combined exposure of AML blasts to cytosine arabinoside and GM-CSF may enhance the intracellular that the clinical use of cytokines to correct therapy-associated myeloid suppression needs to be carefully timed to avoid prouptake of Ara-CTP, thereby increasing anti-leukemic activity. 77 In normal hematopoietic cells, GM-CSF results in tection of the malignant cells from the cytotoxic actions of the therapeutic compounds. increased uptake of dCTP rather than Ara-CTP. 78 Whether this results in differential toxicity to leukemic progenitors
Since the pioneering work of Cannistra and Bettelheim, 85, 86 several studies have been performed. These are outlined in remains uncertain. Table, it is obvious that there is enorchemotherapy for older adults with AML. Bone marrow and peripheral blood is examined prior to initiation of the priming mous variability in the patient population, in the cytokine used, types of therapies administered, and, of course, the therapy and again, 48 h later. Cytokine receptors as well as cell cycle studies and pharmacokinetics are evaluated on each result. Nevertheless, it is important to note that, apart from one report, 81 most controlled trials have confirmed the earlier occasion and study drug (GM-CSF or placebo) is continued until marrow aplasia is achieved, at which point all patients pilot data of Cannistra and Bettelheim 85, 86 that indicated that stimulation of leukemia is not an important clinical problem.
receive open label GM-CSF based on the ECOG data previously reported.
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These studies also demonstrated that, despite reasonable concerns, prolonged aplasia due to susceptibility of residual norAt the present time, unlike the use of cytokines to shorten the period of neutropenia, it seems that the use of GM-CSF or mal progenitors to cytotoxic chemotherapy does not appear to be an important feature.
G-CSF as priming therapy should not be recommended outside well-designed clinical studies. Although most studies It is perhaps important to discuss briefly the one study that demonstrated stimulation of leukemia and a lesser response have not demonstrated beneficial clinical effect, it does not rule out the possibility that certain subtypes of patients may rate among patients receiving E. coli-derived GM-CSF. 81 In this study by Estey et al, 81 56 patients with de novo AML were benefit from such therapy. 97 A recently completed study by the Cancer and Leukemia Group B (CALGB) 98 also demontreated with GM-CSF prior to induction chemotherapy using two different protocols. In the first protocol, GM-CSF was strated no clinical benefit, but although this was a placebocontrolled study, the dose of E. coli-derived GM-CSF was administered at a dose of 125 g/m 2 starting 7 days before induction chemotherapy and in the other study, older individ-3 g/kg, arguably too low to elicit a priming effect. uals (over 60) received 20 g/m 2 for 4 days followed by a dose of 125 g/m 2 for 4 additional days. In other words, the priming therapy was started 8 days prior to chemotherapy.
Induction of differentiation of leukemic cells The growth factor was continued until chemotherapy was completed. The outcome of these data was compared with
In certain cases, cytokines might have the ability to differentiate leukemia cells or progenitors. This has been found to be historical controls for patients receiving induction therapy without GM-CSF. However, just as the patients with GM-CSF the case in the leukemic cell line, HL60 and in some murine models of leukemia 99 where IL-6 resulted in an increase were treated in two different studies, so the comparison historical control patients were also taken from two different in mature cells in marrow and a decrease in blasts and promyelocytes. studies with patients being treated with cytosine arabinoside with or without amsacrine or mitoxantrone. Thus, data from Some clinically available growth factors such as G-CSF and M-CSF may induce differentiation of leukemic progenitors, but this study need to be very cautiously interpreted, especially in light of the accumulating data suggesting that the safety of there is wide heterogeneity in these responses. 100,101 G-CSF, GM-CSF, and IL-3 have been utilized in the treatment of priming with cytokines appears not to be a major clinical issue.
myelodysplasia with some increase in neutrophil counts, suggesting a differentiation effect. It remains unclear in these Nevertheless, the issue remains open and the data are conflicting and confusing. Clearly, large prospective randomized cases whether the leukemic clone is being stimulated to differentiate or whether residual normal progenitors are being studies must be performed before any conclusions can be drawn. At the present time, the ECOG is close to completing stimulated to differentiate. Differentiating cytokines have not seen extensive examina prosepctive double-blind study where patients receive yeastderived GM-CSF or placebo 48 h prior to initiation of standard ation in clinical settings. Using M1 myeloblastic leukemic cells as a model system, cytokines such as IL-6 induce ter-MIP-1 prevented entry of AML blasts into the proliferative phases of the cell cycle and had no effect on IL-1␤ levels.
109 minal differentiation associated with growth arrest whereas negative regulators such as TGF-␤1 induce rapid growth arrest and apoptosis. 102 How differentiation programs interact with programmed cell death pathways remains to be determined.
IFN-␣
Many cytokines which induce differentiation of cultureadapted cells do not induce differentiation of fresh AML Interferon alpha has been found to be a potent inhibitor of AML cell proliferation in vitro.
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blasts.
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Direct anti-leukemic effects of cytokines
IL-10
Interleukin-10 has been found to inhibit spontaneous AML Most cytokines which might have direct anti-proliferative effects on AML blasts have not yet seen widespread clinical blast proliferation in a majority of patients, whereas when cultured in the presence of other exogenous growth factors, ILtrials (Table 11) .
10 demonstrates variable effects. See below under Stem Cell Protection section. patients, addition of IL-6 reduced the stimulatory effect. Interleukin-6 alone has also been reported to inhibit AML in mice and in cell culture.
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Interruption of autocrine-paracrine loops While IL-6 may have an inhibitory effect on proliferation of AML cells in vitro, in a phase II study where eight patients Blast cells from 70% of patients with AML show evidence for autonomous growth, which may relate to the autocrine with AML in first relapse were given IL-6, no responses were seen. 106 These patients had 5-29% marrow leukemic blasts. secretion of growth factors, especially GM-CSF. 112 Patients with autonomous blast growth have a lower remission rate In addition to a direct antileukemic effect, IL-6 may be associated with down-regulation of the apoptosis inhibiting gene, and a higher relapse rate.
113
. AML blasts with autonomous growth are thought to be relatively resistant to programmed bcl-2. Decreased expression of bcl-2 may increase sensitivity of the blasts to apoptotic cell death by chemotherapeutic cell death (apoptosis), and this may be related to the autocrine production of GM-CSF and its upregulation of bcl-2 agents. 107 expression. This increased bcl-2 expression is thought to protect cells from apoptosis induced by cytotoxic drug therapy. 114, 115 G-CSF Interleukin-1 has been reported to play an important role in AML blast proliferation and may be part of autocrine growth In the post-allogeneic bone marrow transplantation setting where relapse of acute myelogenous leukemia has occurred, mechanisms. Freshly obtained leukemic blasts have been shown to spontaneously express the IL-1 gene and to secrete G-CSF has been found to cause disease remission, both hematologic and cytogenetic, with re-establishment of hematointerleukin-1. Some leukemic blasts will proliferate in response to IL-1, and many have IL-1 receptors. Anti-IL-1 antipoieisis of donor origin in three out of seven cases. 108 The mechanisms responsible for this have not been well bodies can inhibit the spontaneous proliferation of leukemic blasts. 116 Estrov et al 117 examined the effect of soluble IL-1 described.
receptors (sIL-1R) and IL-1 receptor antagonist (IL-1RA) on the growth of AML marrow progenitors from 25 patients. IL-1RA competes with IL-1 for receptor binding, but it does not acti-
MIP-1␣
vate the receptor as does IL-1. In blast colony assays, both substances inhibited blast colony formation, and this inhibiMacrophage inflammatory protein-alpha (MIP-1␣), has been found to significantly inhibit primitive and mature AML protory effect was partially reversed by IL-1␤. This inhibition by sIL-1R or IL-1RA could also be demonstrated in the presence genitors up to 79% with sample to sample variability. This could be seen in the presence of GM-CSF, G-CSF, or IL-3.
of fetal calf serum or various CSFs such as GM-CSF, G-CSF, IL-3, and kit ligand. Also, incubation of AML cells with sIL-1R or IL-1RA has been found to reduce the concentration of 132 have reported that IL-3 plus GM-CSF or PIXY-321, IL-3/GM-CSF fusion protein, can improve the selecthe highest levels of GM-CSF and IL-1␤. Antibodies to IL-1 can suppress GM-CSF expression, and antibodies to GM-CSF tivity of cytarabine and paclitaxel in vitro against AML blasts. TGF-␤1 has also been found to have differential effects on can decrease response to IL-1. IL-1 also stimulates G-CSF, GM-CSF, and M-CSF expression in stromal and endothelial normal and leukemic human hematopoietic cell proliferation. 133 Taetle et al 134 have reported three growth patterns cells, so it may indirectly stimulate leukemic blasts in vivo via this mechanism.
120,121 Bruserud 122 has reported that while with TGF-␤1 seen with AML cells: sensitivity to growth inhibition, resistance, and factor-dependent resistance. Some endogenous IL-1 secretion varies widely between individual cases of AML, inhibition of IL-1 decreases blast secretion of effects of TGF-␤ on AML cells occur through stimulation of apoptosis. In AML, TGF-␤1 almost completely abolished the IL-1 alpha, G-CSF, GM-CSF, TNF-␣, and IL-6. In the presence of exogenous growth factors, the effects of IL-1 inhibition on growth stimulated with G-CSF, whereas in normal hematopoietic progenitors, the growth stimulated by G-CSF was unafblast proliferation are variable. The ultimate effect of IL-1 on AML blasts may therefore be dependent on the cytokine netfected. TGF-␤1 was also found to inhibit mRNA expression by AML blasts for c-myc and/or c-myb. It was suggested that work in the AML blast microenvironment in vivo.
Interleukin-6 has also been associated with autonomous growth suppression by TGF-␤1 appeared to increase with the progression of clonal evolution in hematologic malignancies. growth of AML blasts in vitro. Forty per cent of AML blasts with autonomous growth have been reported to exhibit abnor-MIP-1␣ has also been reported to decrease the entry of early hematopoietic progenitors into cell cycle, while having no malities of retinoblastoma (Rb) protein expression. The Rb protein is a known transcriptional repressor of the IL-6 prosimilar effect on the cycling status of various leukemic cell populations. This may also suggest a possible use for this Cmoter, and the expression of IL-6 has been found to be significantly associated with loss of Rb protein expression. 123 C chemokine as a stem cell protectant. 135 Blasts from four patients which secreted high levels of IL-6 exhibited autonomous growth in vitro which could be partially suppressed by antisense oligonucleotides to IL-6.
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Summary
Murohashi et al
125 have reported that a specific neutralizing antibody against TNF-␣ was able in vitro to reduce the Over the past decade, with the advent of hematopoietic growth factors, major strides and multiple studies have growth-stimulating effect of IL-3 on the blasts of 11 of 14 patients. The effect of anti-TNF␣ was greater than that of antiattempted to define the use of these cytokines in acute leukemia. It is perhaps disappointing that, after so many studies, IL-1␣ and anti-IL-1␤. Constitutive TNF␣ transcript was observed in five of these patients, and TNF␣ protein was so many question marks remain. Nevertheless, their role in induction therapy seems to be established. They are clearly present in culture supernatant. Anti-TNF␣ inhibited the accumulation of TNF␣ transcript, suggesting that membraneeffective, although the magnitude of this effect continues to be debated. The issue of cytokine use as priming therapy is integrated TNF␣ may be partly responsible for the induction of the TNF␣ mRNA, another possible autocrine mechanism as yet unresolved; most studies do not demonstrate a positive effect. Intriguing data regarding the potential for enhancing with potential effects on AML blasts.
To assess whether autonomous growth characteristics have anti-microbial function should hopefully be resolved over the next few years. What is perhaps most reassuring is that the any clinical relevance in AML, Hunter et al 126 compared the CR rates in those patients whose leukemic cells exhibited issue of safety, which precluded for a considerable period of time, the development of clinical trials in acute leukemia, has either partial or totally autonomous growth in a blast cell colony assay. Patients whose blasts exhibited autonomous been firmly laid to rest. The use of growth factors to protect normal stem cells during treatment of leukemia and to induce growth in vitro has a significantly lower CR rate (57%) compared with the patients whose blasts had nonautonomous leukemic cell differentiation has not yet been the subject of clinical trials. Also, growth factors are likely targets for the growth (94%). The widespread constitutive cytokine expression by leukemic blasts may therefore play a role in interruption of autocrine leukemic blast or progenitor cell growth, but again, few clinical observations are published. driving the leukemic process.
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With the ongoing cloning of new growth factors active both in normal hematopoiesis and in leukemogenesis, the role of Stem cell protection Both IL-1 and TNF have been reported to protect normal pro- Table 12 Mechanisms to interrupt autocrine stimulation of AML genitors from the effects of 4-hydroperoxycyclophosphamide, blasts a cyclophosphamide cogener utilized in marrow purging protocols. 128 Leukemic cells lines or fresh leukemic samples were 
